Skip to main content

Table 4 Background of patients stratified by administration of remdesivir (with or without remdesivir) after matching

From: Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study

  Without remdesivir With remdesivir p valuea
n % n %
Age
 < 60 90 30.6 30 30.6 1.000
 60 s 51 17.3 17 17.3  
 ≥ 70 153 52.0 51 52.0  
Gender
 Male 210 71.7 67 68.4 0.524
 Female 83 28.3 31 31.6  
Primary disease
 Chronic glomerulonephritis 40 15.1 20 22.5 0.372
 Diabetes mellitus 149 56.2 43 48.3  
 Nephrosclerosis 39 14.7 12 13.5  
 Others 37 14.0 14 15.7  
Duration of dialysis
 < 1 year 37 12.9 14 14.4 0.754
 1 to < 5 years 100 34.8 31 32.0  
 5 to < 10 years 72 25.1 30 30.9  
 10 to < 15 years 42 14.6 13 13.4  
 ≥ 15 years 36 12.5 9 9.3  
Complication
 Hypertension
  No 156 55.1 42 42.9 0.046
  Yes 127 44.9 56 57.1  
 Diabetes mellitus
  No 124 43.5 46 46.9 0.558
  Yes 161 56.5 52 53.1  
 Cardiovascular disease
 No 156 56.5 49 51.6 0.406
  Yes 120 43.5 46 48.4  
Chronic respiratory disease
  No 249 89.6 83 87.4 0.571
  Yes 29 10.4 12 12.6  
 Peripheral arterial disease
  No 230 84.9 75 78.9 0.201
  Yes 41 15.1 20 21.1  
 Malignancy
  No 234 84.2 83 87.4 0.509
  Yes 44 15.8 12 12.6  
 Number of complication
  0 38 13.1 10 10.2 0.778
  1 84 29.1 29 29.6  
   ≥ 2 167 57.8 59 60.2  
Oxygenation
 No 69 23.5 23 23.5 1.000
 Yes 159 54.1 53 54.1  
 Ventilator or ECMO 66 22.4 22 22.4  
  1. ECMO extracorporeal membrane oxygenation
  2. aFisher’s exact test